CAS: 4175-66-0; 2,5-Dimethylthiazole

该化合物是一种有机化合物,其特征是三硝基甲醇环,这是一个五人组成的含有硫磺和氮原子的环环结构,该化合物在2和5个位置的三甲诺醇环上有两组附着的甲基,有助于其独特的化学特性;该化合物一般是一种无色的黄色黄色液体,其香味强,独特性味通常被描述为香味或肉类,使其在调味应用中有用. 2,5-二甲基甲诺醇在有机溶剂中溶解,且在水中溶解性有限.该化合物以其在各种生物化学工艺中的作用著称,可通过不同方法合成,包括适当的三甲诺醇前体的反应.此外,该化合物因其潜在的生物活动,对农业化学和药物领域很感兴趣.安全数据表明,应当谨慎处理,因为接触时可能对健康造成危害.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

2-methylthiazole methyl iodide 2,5-Dimethyl-3-phenacyl-thiazolium 5-(bromomethyl)-2-methylthiazole

合成工艺路线路线简述

    📜2,5-二甲基恶唑置于aluminum Oxide,硫化氢体系中,化学反应生成 2,5-二甲基噻唑
    参考文献:Jur'Ew; Shukowa,Zhurnal Obshchei Khimii,1958,Vol. 28,P. 7,10; Engl. Ausg. S. 5,7
    标题:Jur'Ew; Shukowa,Zhurnal Obshchei Khimii,1958,Vol. 28,P. 7,10; Engl. Ausg. S. 5,7

    专利信息


    专利号:WO-2023086801-A1
    优先权日:2021-11-09
    标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    发明人:HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
    权利人:VIGIL NEUROSCIENCE INC
    摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

    专利号:US-2022356182-A1
    优先权日:2009-03-27
    标题 :Inhibitors of hepatitis c virus replication
    发明人:COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOLL RICHARD; ZHONG BIN; ZHU JIAN
    权利人:MERCK SHARP & DOHME
    摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

    专利号:US-9802952-B2
    优先权日:2013-07-15
    标 题:Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives
    发明人:KOPETZKI DANIEL; MCQUADE DAVID TYLER; SEEBERGER PETER H; GILMORE KERRY
    权利人:MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V; MAX-PLANK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V
    摘要:The present invention is directed to a method for continuous production of dihydroartemisinin and also artemisinin derivatives derived from dihydroartemisinin by using artemisinin or dihydroartemisinic acid (DHAA) as starting material as well as to a continuous flow reactor for producing dihydroartemisinin as well as the artemisinin derivatives. It was found that the reduction of artemisinin to dihydroartemisinin in a continuous process requires a special kind of reactor and a special combination of reagents comprising a hydride reducing agent, at least one activator such as an inorganic activator, at least one solid base, at least one aprotic solvent and at least one C 1 -C 5 alcohol.

    专利号:US-9090661-B2
    优先权日:2009-03-27
    标 题:Inhibitors of hepatitis C virus replication
    发明人:COBURN CRAIG A; MCCAULEY JOHN A; LUDMERER STEVEN W; LIU KUN; VACCA JOSEPH P; WU HAO; HU BIN; SOLL RICHARD; SUN FEI; WANG XINGHAI; YAN MAN; ZHANG CHENGREN; ZHENG MINGWEI; ZHONG BIN; ZHU JIAN
    权利人:MERCK SHARP & DOHME
    摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

    专利号:US-6225341-B1
    优先权日:1995-02-27
    标 题:Compounds and methods for synthesis and therapy
    发明人:BISCHOFBERGER NORBERT W; KIM CHOUNG U; LEW WILLARD; LIU HONGTAO; WILLIAMS MATTHEW A
    权利人:GILEAD SCIENCES INC
    摘要:Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

    专利号:US-8772301-B2
    优先权日:2009-12-18
    标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
    发明人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
    权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
    摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Koutentis, P. A.; Ioannidou, H. A., Science of Synthesis Knowledge Updates, (2010) 1, 348.
    摘要:P. Goursot and I. Wadso. Acta Chem. Scand. 20, 1314 (1966).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知